arrow_back Back Filing freshness 10-Q Q1 FY2025 SEC EDGAR

Cell Source, Inc.

CLCS
Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
48 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
75
Health
Good
Bullish
auto_awesome

Analytical Summary

Cell Source, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap
Dividend Yield
Revenue Growth
Op. Margin
ROIC 3.9%
FCF / Share $-0.01
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close.

48-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-1.48M
↓ -16.2%
FCF / Share Free cash flow per share
$-0.01
↓ -210.6%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
88
Cash Quality
41

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 48 quarters